Shoulson I
Department of Neurology, University of Rochester Medical Center, School of Medicine and Dentistry, Suite 212, 1351 Mt. Hope Avenue, Rochester, NY 14620, USA.
Science. 1998 Nov 6;282(5391):1072-4. doi: 10.1126/science.282.5391.1072.
Viewpoint The experimental therapeutics of neurodegenerative disorders is in its infancy, but neuroprotective strategies are already being applied in healthy persons at high risk of developing disease as well as in patients with manifest illness. Knowledge of etiology and pathogenesis, improved design of clinical trials, the development of biological markers, the advent of genetic animal models, the enhanced identification of susceptibility factors, and more effective drug delivery-such advances have improved the prospects for forestalling onset of illness and clinical decline in the growing numbers of people affected by neurodegenerative disorders.
观点 神经退行性疾病的实验性治疗尚处于起步阶段，但神经保护策略已应用于有高疾病发生风险的健康人群以及已发病患者。病因学和发病机制的知识、临床试验设计的改进、生物标志物的研发、基因动物模型的出现、易感性因素识别的加强以及更有效的药物递送——这些进展改善了延缓神经退行性疾病影响人数不断增加的人群发病和临床衰退的前景。
